Alpha-1 antitrypsin deficiency (AATD) is the only readily identifiable monogenic cause of
COPD. To date the only condition-specific treatment for AATD-associated COPD is weekly …

Rationale: Intravenous plasma-purified alpha-1 antitrypsin (IV-AAT) has been used as therapy
for alpha-1 antitrypsin deficiency (AATD) since 1987. Previous trials (RAPID and RAPID-…

Background Patients with severe coronavirus disease 2019 (COVID-19) develop a febrile
pro-inflammatory cytokinemia with accelerated progression to acute respiratory distress …

Introduction Alpha1 antitrypsin deficiency (AATD), a common hereditary disorder affecting
mainly lungs, liver and skin has been the focus of some of the most exciting therapeutic …

Objectives The primary objective is to demonstrate that, in patients with PCR-confirmed
SARS-CoV-2 resulting in Acute Respiratory Distress Syndrome (ARDS), administration of 120mg/…

Background & Aims α1-Antitrypsin (AAT) is a major protease inhibitor produced by hepatocytes.
The most relevant AAT mutation giving rise to AAT deficiency (AATD), the ‘Pi∗Z’ variant, …

Patients with severe alpha-1 antitrypsin deficiency (AATD) are at increased risk for the
development of chronic obstructive pulmonary disease (COPD), particularly if they smoke. This, …

Background: Patients with alpha-1 antitrypsin deficiency (AATD) exhibit dysregulated
inflammatory responses and a predilection for autoimmunity. While the adverse event (AE) profiles …

Background: From March 2006 to October 2010, 140 patients with alpha-1 antitrypsin (AAT)
deficiency who received either intravenous AAT augmentation or placebo in the RAPID …

Background Remediation of underperforming students is recognised as an important tool in
medical education; however, there is no universally agreed approach. Aims This study …